Trial Profile

Routine Versus Aggressive Upstream Rhythm Control for Prevention of Early Atrial Fibrillation in Heart Failure: RACE 3

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 10 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amiodarone (Primary) ; Dronedarone (Primary) ; Flecainide (Primary) ; Sotalol (Primary)
Indications Atrial fibrillation
Focus Therapeutic Use
Acronyms RACE-3

Most Recent Events

17 Aug 2021 Status has been changed to completed.
04 Sep 2013 Accrual to date is 70% according to United Kingdom Clinical Research Network.
07 Mar 2013 Planned End Date changed from 31 Jul 2013 to 1 Jul 2019 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com